期刊文献+

喹硫平治疗综合医院住院患者并发谵妄的临床疗效分析 被引量:5

The clinical analysis of Quetiapine to treat 87 hospitalized patients with delirium
下载PDF
导出
摘要 目的:研究喹硫平对综合医院住院患者伴急性谵妄的临床疗效。方法:将87例确诊为急性谵妄的患者随机分为两组,研究组44例和对照组43例。在积极治疗原发病的同时,治疗组患者合并使用喹硫平治疗,对照组患者合并使用奥氮平治疗。在治疗前,治疗1周、2周后分别使用简明精神病量表(BPRS)、谵妄评定量表(CAM-CR)、临床总体印象量表(CGI)和药物副作用量表(TESS)给予评分。结果:①喹硫平组和奥氮平组治疗后显效率分别为84.66%与85.37%,两组显效率差异无统计学意义(P>0.05)。②与治疗前相比,研究组和对照组在治疗1周后的CAM-CR和CGI量表评分均有改善(P<0.05);治疗2周后,研究组和对照组患者改善更明显(P<0.01),两组间差异无统计学意义(P>0.05)。③不良反应总的发生率奥氮平组明显高于喹硫平组,两组差异有统计学意义(P<0.05)。结论:喹硫平与奥氮平治疗谵妄疗效相当,喹硫平不良反应小,可以作为一线药物用于谵妄的治疗。 Objective:To study the clinical efficacy of Quetiapine to treat the hospitalized patients with acute delirium.Methods:There were 87 cases diagnosed as delirium.They were randomly divided into two groups,the study group had 44 cases and the control group had 43 cases.In the original disease were treated actively simultaneously,we amalgamative used Quetiapine in the study group and Olanzapine in the control group.Before the treatment,one week and two weeks after the treatment,we respectively used BPRS,CAM-CR,CGI,and TESS in turn to give grades.Results:①After the treatment,the effective rate was 84.66% in Quetiapine group and 85.37% in Olanzapine group,there was no significant difference between the two groups(P0.05).②To compare with before the treatment,the grades of CAM-CR and CGI had improved in both groups after one week treatment(P0.05),and there were more improvement after two weeks treatment(P0.01),there was no significant difference between the two groups(P0.05).③The overall incidence of adverse events of Olanzapine group was significantly higher than those of the Quetiapine group,the difference was significant(P0.05).Conclusion:Compared with Olanzapine,Quetiapine has the same effect in treating delirium,and has fewer adverse reactions,so Quetiapine can be the first-line drug for the treatment of delirium.
出处 《中国医药导报》 CAS 2011年第15期31-32,35,共3页 China Medical Herald
关键词 谵妄 喹硫平 奥氮平 Delirium Quetiapine Olanzapine
  • 相关文献

参考文献11

  • 1Polder man KH. Screening methods for delirium: don't get confused [J]. Intensive Care Med,2007,33:3-5.
  • 2Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care un it [J]. JAMA,2004,291 ( 14): 1753-1762.
  • 3Siddiqi N, House AO, Holmes AO. Occurrence and outcome of delirium in medical in patients: a systematic literature review [J]. Age and Ageing,2006,35(4):350-364.
  • 4任艳萍,蔡焯基.老年性谵妄的研究进展[J].国外医学(精神病学分册),2000,27(1):16-20. 被引量:23
  • 5Levenson JL. Textbook of Psychosomatic Medicine [M]. England: Amer- ican Psych iatric Publishing Inc,2005:91-130.
  • 6王新德.老年人急性意识模糊状态:附7例临床分析[J].中华老年医学杂志,1991,10(2):71-74. 被引量:47
  • 7赵海宁,袁成林.综合科老年期谵妄临床观察[J].临床精神医学杂志,2002,12(2):92-92. 被引量:11
  • 8黄继忠,张明园.非典型抗精神病药治疗精神分裂症的临床应用评价[J].中国医院用药评价与分析,2005,5(2):75-80. 被引量:58
  • 9Sasaki Y, Matsuyama T, InoueS, et al. A prospective, open label, flexible-dose study of quetiapine in the treatment of delirium [J]. J Clin Psychiatry,2003,64( 11 ): 1316-1321.
  • 10Kim KY, Bader GM, Kotlyar V, et al. Treatment of delirium in older adults with quetiapine [J]. J Geriatric Psychiatry Neural,2003,16(1): 29-31.

二级参考文献51

  • 1江英才,中华老年医学杂志,1985年,3期,190页
  • 2Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia[ J]. N Engl J Med , 2002,346:16.
  • 3Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine,ri speridone, sulpiride, or haloperidol[ J]. Eur Arch Psychiatry Clin Neurosci ,2001,251: 141.
  • 4Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40and 20 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4 - week placebo controlled trial [J]. Psychopharmacology, 1998,140:173.
  • 5Goff DC, Posever T, Herz L, et al. An exploratory haloperidol - controlled dose finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorde [ J ]. J Clin Psychopharmacol , 1998,18:296.
  • 6Pezawas L, Quiner S, Moertl D, et al. Efficacy, cardiac safety and tolerability of sertindole:a drug surveillance [J]. Int Clin Psychopharmacol,2000,15 :207 .
  • 7Van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose - ranging trial of sertindole in patients with schizophrenia[J]. Psychopharmacolog y, 1996,124:168.
  • 8Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled,dose - response study of sertindole and haloperidol in the treatment of schizophrenia[ J]. Am J Psychiatry, 1997,154:782.
  • 9Peuskens J, Bech P, Moller H J, et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia [ J ]. Psychiatry Res, 1999,88 ( 2 ): 107.
  • 10Hwang TJ, Lin SK, Lin HN. Efficacy and safety of zotepine for the treatment of Taiwan Residents schizophrenic patients: a double - blind comparison with haloperidol[J]. J Formos Med Assoc,2001,100:811.

共引文献131

同被引文献43

  • 1田国强,甘建光,秦国兴.奥氮平治疗酒精所致精神障碍的临床疗效观察[J].浙江临床医学,2005,7(9):969-970. 被引量:2
  • 2沈渔邨.精神病学[M].5版.北京:人民卫生出版社.2009:838.
  • 3沈渔邮.精神病学[M].3版.北京:人民卫生出版社,1995:185-186.
  • 4张明圆.精神科评定量表手册[M].长沙:湖南科学技术出版社,1993.34-41.
  • 5中华医学会精神科分会.中国精神障碍分类与诊断标准[M].3版.济南:山东科学技术出版社,2001:108-1150.
  • 6郝伟.精神病学[M].6版.北京:人民卫生出版社,2010: 196.
  • 7Giovanni M, Paolo P,Etena S M,et al. Delirium: Clinical approach and prevention [J].Best Practice & Research Clinical Anaesthesi- ology, 2012, 26(3):311-326.
  • 8Sung-Wan Kim,Joon-An YooI.Risperidone versus olanzapine for the treatment of delirium[J]. Human sychopharmacology: Clinical and Experimental,2010,25(4):298-302.
  • 9American Psychiatric Association.Diagnostic and Statistical Man- ual of Mental Disorders DSM-IV-TR (Text Revision) [M]. American Psychiatric Association, 2000:63.
  • 10Overall J E, Gorham D R. The brief psychiatric rating scale[M]. Psychological Reports,1962:799-812.

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部